Literature DB >> 12173151

Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus.

Renaud Verdon1, Michel Daudon, Françoise Albessard, Jean-Louis Brefort, Claude Bazin.   

Abstract

We report the first case of acute cholecystitis due to indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus who had been receiving indinavir for 56 months. Infrared spectroscopy demonstrated that the gallstone was composed of indinavir monohydrate (50%), calcium bilirubinate (28%), calcium palmitate (10%), cholesterol (7%), and proteins (5%). The role of high-level chronic unconjugated hyperbilirubinemia coupled with high blood concentrations of indinavir is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173151     DOI: 10.1086/341982

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Possible Atazanavir-Induced Cholelithiasis in a Pregnant Woman: A Case Report.

Authors:  Claire Bianchi; Kateri Lévesque; Marc Boucher; Ema Ferreira
Journal:  Can J Hosp Pharm       Date:  2016-08-31

Review 2.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 3.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Hepatic expression of cholesterol regulating genes favour increased circulating low-density lipoprotein in HIV infected patients with gallstone disease: a preliminary study.

Authors:  Suman Mewa Kinoo; Anil A Chuturgoon; Bugwan Singh; Savania Nagiah
Journal:  BMC Infect Dis       Date:  2021-03-23       Impact factor: 3.090

6.  Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Authors:  Yohei Hamada; Takeshi Nishijima; Hirokazu Komatsu; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.